Document Detail


Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.
MedLine Citation:
PMID:  20169356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We have previously shown that bevacizumab, but not ranibizumab, is taken up by porcine RPE cells. In this study, the effects of bevacizumab and ranibizumab on proliferation, wound healing and phagocytosis of the RPE were investigated. METHODS: Primary porcine RPE cell culture were prepared from fresh eyes, cultivated and treated with clinically relevant concentrations of bevacizumab or ranibizumab respectively. Proliferation was investigated in a proliferation assay, wound healing in a wound scratch assay and phagocytosis was investigated by feeding RPE cells photoreceptor outer segment-opsonized FITC-labeled latex beads. RESULTS: Bevacizumab, and to a lesser extend ranibizumab, impair the proliferation of RPE cells but do not affect wound healing. Bevacizumab, but not ranibizumab, reduces the phagocytotic function of RPE cells. CONCLUSIONS: The uptake of bevacizumab reduces phagocytosis in RPE cells, which indicates possible long-term effects of repeated bevacizumab treatment.
Authors:
Alexa Klettner; Friederike Möhle; Johann Roider
Related Documents :
1361306 - Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear a...
17975226 - Efficient in vitro labeling of human neural precursor cells with superparamagnetic iron...
20213856 - Optimization of magnetosonoporation for stem cell labeling.
18264776 - Effects of an imprinting procedure on cell proliferation in the chick brain.
22970166 - α-tomatine-mediated anti-cancer activity in vitro and in vivo through cell cycle- and ...
537676 - A basic program to correct for split cell error in particles classified by the logarith...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-19
Journal Detail:
Title:  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie     Volume:  248     ISSN:  1435-702X     ISO Abbreviation:  Graefes Arch. Clin. Exp. Ophthalmol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-04-26     Completed Date:  2010-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8205248     Medline TA:  Graefes Arch Clin Exp Ophthalmol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  819-24     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Kiel,, Arnold-Heller-Str. 3, Haus 25, 24105, Kiel, Germany. aklettner@auge.uni-kiel.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / pharmacology*
Animals
Antibodies, Monoclonal / pharmacology*
Cell Proliferation / drug effects
Cells, Cultured
Phagocytosis / drug effects*
Retinal Photoreceptor Cell Outer Segment / metabolism
Retinal Pigment Epithelium / cytology,  physiology*
Swine
Wound Healing / drug effects
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/bevacizumab; 0/ranibizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of sociodemographic and health variables on mini-mental state examination in a community-base...
Next Document:  Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization a...